A Forbion-funded startup bought the rights to Amgen's CETP inhibitor, and is giving the cholesterol drug another go
Forbion-funded startup NewAmsterdam Pharma has acquired the rights to obicetrapib: the CETP inhibitor that CEO Michael Davidson always thought would be the “crowning” of his career.
The announcement comes five years after Forbion sold Dezima Pharma and obicetrapib, its sole product, to Amgen for an up-front payment of $300 million. Amgen halted development in 2017, shortly after Eli Lilly, Pfizer, Roche and Merck walked away from their own CETP drugs. Former Pfizer R&D chief John LaMattina even suggested that Amgen might be better off cutting its losses just weeks after acquiring the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.